Xarelto Tablet, Film Coated
Product Images NDC 50090-4469

34 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Xarelto (NDC 50090-4469). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Xarelto 01)

Figure 1 (Xarelto 01)
A forest plot comparing hazard ratios and 95% confidence intervals between Rivaroxaban and Warfarin across multiple patient subgroups, including prior Warfarin/VKA use, age categories, gender, weight, prior stroke/TIA, diabetic status, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization. The plot visualizes favoring either Rivaroxaban or Warfarin with markers and horizontal lines representing confidence intervals, along with corresponding numerical hazard ratios and confidence intervals to the right.*
FDA Label Image

Chemical Structure (Xarelto 02)

Chemical Structure (Xarelto 02)
A forest plot chart comparing the incidence of major bleeding events according to ISTH criteria between Xarelto plus aspirin and aspirin alone. The chart breaks down data by age, sex, region, weight, eGFR, MI history, stroke history, heart failure, diabetes, CAD, and PAD, showing hazard ratios with 95% confidence intervals for each subgroup.*
FDA Label Image

Figure 2 (Xarelto 03)

Figure 2 (Xarelto 03)
Chemical structure of rivaroxaban, the active ingredient in Xarelto 10 mg oral film-coated tablets by A-S Medication Solutions. The diagram shows the molecular structure with rings and functional groups characteristic of rivaroxaban.*
FDA Label Image

Figure 3 (Xarelto 04)

Figure 3 (Xarelto 04)
A chart depicting pharmacokinetic (PK) fold change and 90% confidence intervals for rivaroxaban in various population groups, including end-stage renal disease, renal impairment, age, body weight, and hepatic impairment. The chart compares Cmax and AUC values relative to a reference, illustrating exposure changes across these conditions.*
FDA Label Image

Figure 4 (Xarelto 05)

Figure 4 (Xarelto 05)
A pharmacokinetic chart showing the fold change and 90% confidence intervals in Cmax and AUC of various interacting drugs relative to rivaroxaban alone. The chart categorizes interacting drugs by their mechanism, including combined P-gp and strong or moderate CYP3A inhibitors and inducers, and other drugs. It visually presents changes in drug exposure for agents like ketoconazole, ritonavir, erythromycin, and rifampicin, among others.*
FDA Label Image

Figure 5 (Xarelto 06)

Figure 5 (Xarelto 06)
A line graph comparing cumulative event rates (%) over time (days from randomization) for two drugs: Xarelto and Warfarin. The solid line represents Xarelto and the dashed line Warfarin. The graph includes a hazard ratio (HR) with 95% confidence interval (CI) at 0.88 (0.74, 1.03). The number of subjects at risk for each drug is indicated below the x-axis at various time points up to 900 days.*
FDA Label Image

Figure 6 (Xarelto 07)

Figure 6 (Xarelto 07)
A forest plot displaying hazard ratios and 95% confidence intervals comparing rivaroxaban and warfarin across various patient subgroups. The graph shows favorability ranges on the x-axis with data points indicating hazard ratios for groups such as age, gender, weight, prior stroke, diabetic status, kidney function, geographic region, and ASA use at randomization, illustrating relative risk metrics between the two treatments.*
FDA Label Image

Figure 7 (Xarelto 08)

Figure 7 (Xarelto 08)
A Kaplan-Meier cumulative event rate curve comparing Xarelto (rivaroxaban) and Enoxaparin/VKA over days from randomization up to 360 days. The Y-axis shows cumulative event rate percentage. The chart includes patient numbers at risk over time for each treatment group below the X-axis and a hazard ratio (HR) with 95% confidence interval (CI) noted in the graph.*
FDA Label Image

Figure 8 (Xarelto 09)

Figure 8 (Xarelto 09)
A cumulative event rate graph comparing Enoxaparin/VKA and Xarelto with respect to days from randomization over a 360-day period. The y-axis shows the cumulative event rate in percentage, and the x-axis shows days from randomization. The number of patients at risk at multiple time points is listed below the graph for both treatments, with hazard ratio and confidence interval noted on the image.*
FDA Label Image

Figure 9 (Xarelto 10)

Figure 9 (Xarelto 10)
A Kaplan-Meier curve comparing cumulative event rates (%) over 367 days from randomization for Xarelto versus Aspirin. The solid line represents Xarelto, and the dashed line represents Aspirin, showing lower cumulative events in Xarelto. Below the graph, the number of subjects at risk for each group is listed at different time points. The hazard ratio with 95% confidence interval is displayed in the bottom right.*
FDA Label Image

Figure 10 (Xarelto 11)

Figure 10 (Xarelto 11)
A forest plot comparing the primary efficacy outcome of Xarelto (rivaroxaban) plus aspirin versus aspirin alone across various subgroups such as age, sex, region, weight, eGFR, MI history, stroke history, heart failure history, baseline diabetes, CAD, PAD, and combined CAD with PAD. The plot shows hazard ratios (HR) with 95% confidence intervals (CI), indicating the relative effect of treatments for each subgroup.*
FDA Label Image

Figure 11 (Xarelto 12)

Figure 11 (Xarelto 12)
A cumulative probability line graph comparing Xarelto plus Aspirin versus Aspirin alone over time in days from randomization, with probability percentage on the y-axis and days on the x-axis. The graph includes a hazard ratio of 0.76 (95% CI 0.66-0.86) for Xarelto plus Aspirin versus Aspirin, as well as subject counts at risk at various time points.*
FDA Label Image

Figure 12 (Xarelto 13)

Figure 12 (Xarelto 13)
A forest plot comparing the primary efficacy outcome of Xarelto (rivoraxaban) versus placebo across various patient subgroups, including age, sex, weight, kidney function (eGFR), diabetes status, coronary artery disease, randomization strata, clopidogrel use, history of revascularization, and critical limb ischemia categories. The plot includes hazard ratios (HR) with 95% confidence intervals, with a central line indicating equivalence and markers showing favorability towards Xarelto or placebo.*
FDA Label Image

Image (Xarelto 14)

Image (Xarelto 14)
An illustration of a purple syringe with measurement markings in milliliters from 0.4 to 3, presented in color-coded segments along the barrel. The plunger is also purple, and the tip is capped with a white cover. The image shows the full length of the syringe.*
FDA Label Image

Image (Xarelto 15)

FDA Label Image

Image (Xarelto 16)

Image (Xarelto 16)
Illustration of a purple oral syringe marked with volume graduations from 0.5 mL to 5 mL. The syringe features a transparent tip and a plunger handle at the top for liquid measurement and administration.*
FDA Label Image

Image (Xarelto 17)

Image (Xarelto 17)
An instructional illustration of a purple oral syringe used for medication dosing. The syringe displays color-coded measurement markings along its clear barrel from 0.5 mL to 3 mL. The tip is labeled at the top, and the plunger is labeled at the bottom. The illustration visually explains the parts of the oral syringe for accurate medication administration.*
FDA Label Image

Image (Xarelto 18)

Image (Xarelto 18)
An instructional diagram showing a brown glass bottle with a white cap and a bottle adaptor. Labels point to the cap and bottle adaptor, with a red warning text stating not to remove the bottle adaptor.*
FDA Label Image

Image (Xarelto 19)

Image (Xarelto 19)
Illustration showing a medication bottle labeled Xarelto (rivoraxaban) film-coated tablets. The focus is on the label area circle emphasizing where to check the "Discard after" date for proper medication use timing.*
FDA Label Image

Image (Xarelto 20)

Image (Xarelto 20)
An instructional illustration showing handwashing, with water pouring over two hands lathered with soap bubbles. This type of diagram is typically used to demonstrate proper hand hygiene technique.*
FDA Label Image

Image (Xarelto 21)

Image (Xarelto 21)
An instructional illustration showing a hand holding and gently shaking a bottle. The text 'SLOW!' in blue indicates the shaking should be done slowly, with motion lines near the bottle and hand emphasizing the gentle movement.*
FDA Label Image

Image (Xarelto 22)

Image (Xarelto 22)
Illustration showing a visual check of the bottom of a bottle or container from an eye-level perspective, highlighting the verification of a mark or feature on the base.*
FDA Label Image

Image (Xarelto 23)

Image (Xarelto 23)
A vertical bar chart resembling a syringe depicting volume measurements from 0.8 mL to 3 mL and 5 mL at the bottom, segmented into multiple colored horizontal bands corresponding to various volume increments.*
FDA Label Image

Image (Xarelto 24)

Image (Xarelto 24)
A dosing measurement table displaying combined mL volumes corresponding to total doses of 7.5 mL, 10 mL, 15 mL, and 20 mL. The table specifies how to measure these doses by combining increments of 5 mL and 2.5 mL units.*
FDA Label Image

Image (Xarelto 25)

Image (Xarelto 25)
Illustration showing a hand holding a vial and a syringe, with an arrow indicating to pull or draw liquid from the vial into the syringe. The vial is highlighted in a circular inset, suggesting how to prepare the medication dose for injection.*
FDA Label Image

Image (Xarelto 26)

Image (Xarelto 26)
Instructional illustration showing two hands preparing a medication bottle. One hand holds a bottle while the other inserts a bottle adaptor into the bottle opening, with a closeable cap nearby. The image highlights the use of the bottle adaptor in medication preparation or dosing.*
FDA Label Image

Image (Xarelto 27)

Image (Xarelto 27)
Instructional illustration depicting a person holding a syringe vertically with one hand and pressing down on its plunger with the other. A blue downward arrow emphasizes the plunger's downward motion, suggesting injection or dispensing of medication.*
FDA Label Image

Image (Xarelto 28)

FDA Label Image

Image (Xarelto 29)

Image (Xarelto 29)
An instructional illustration showing a hand applying pressure to a purple tube near its opening, with an inset circle zooming in on bubbles inside the tube at the top. This image appears to demonstrate priming or air bubble removal from a tube or applicator device.*
FDA Label Image

Image (Xarelto 30)

Image (Xarelto 30)
An instructional illustration showing a hand holding a finger with the other hand pressing the plunger of a small syringe or lancet device. A blue upward arrow below indicates the direction of pressing or movement.*
FDA Label Image

Image (Xarelto 31)

Image (Xarelto 31)
Illustration showing a person holding a bottle in one hand while using the other hand to pull a dropper or a similar instrument vertically upward above the bottle. The image demonstrates the action of removing the dropper from the bottle, indicated by an upward arrow.*
FDA Label Image

Image (Xarelto 32)

Image (Xarelto 32)
An instructional illustration showing a person using an oral applicator to administer medication inside a child's mouth. The image focuses on positioning the applicator near the cheek for proper delivery.*
FDA Label Image

Image (Xarelto 33)

Image (Xarelto 33)
An instructional illustration showing a hand holding an open test tube and another hand holding a purple stick or similar object, with water droplets falling from above, indicating the action of rinsing or washing the test tube or object under water.*
FDA Label Image

Label Image (Lbl500904469)

Label Image (Lbl500904469)
Label for Xarelto 10 mg film-coated tablets, an oral human prescription drug containing rivaroxaban, manufactured by A-S Medication Solutions. The label states each tablet contains 10 mg of rivaroxaban and the package contains 90 tablets. Storage instructions recommend room temperature. The label also includes the product and NDC numbers along with a dosage instruction QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.